Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations

Bioanalytical Systems Inc. (BASI)

4.61   -0.34 (-6.87%) 02-14 16:00
Open: 4.86 Pre. Close: 4.95
High: 4.86 Low: 4.3
Volume: 123,146 Market Cap: 50M
Bioanalytical Systems Inc is a contract research organization providing drug discovery and development services and analytical instruments. Its customers and partners include pharmaceutical, biotechnology, academic and government organizations.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 5.028 - 5.063 5.063 - 5.09
Low: 4.219 - 4.261 4.261 - 4.293
Close: 4.549 - 4.609 4.609 - 4.655

Technical analysis

as of: 2020-02-14 4:26:49 PM
Stoxline posted a SELL today, same as yesterday. Downward movement continues.
Target: Six months: 6.61     One year: 7.59
Support: Support1: 4.30    Support2: 3.58
Resistance: Resistance1: 5.66    Resistance2: 6.50
Pivot: 5.05
Moving Average: MA(5): 4.95     MA(20): 5.18
MA(100): 4.62     MA(250): 3.14
MACD: MACD(12,26): -0.05     Signal(9): 0.01
Stochastic oscillator: %K(14,3): 21.86     %D(3): 19.12
RSI: RSI(14): 37.98
52-week: High: 6.50  Low: 1.40  Change(%): 227.0
Average Vol(K): 3-Month: 6147  10-Days: 3168

Price, moving averages and Bollinger Bands

Price and moving averages has closed below its Short term moving average. Short term moving average is currently above mid-term; AND above long term moving averages. From the relationship between price and moving averages; we can see that: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.
BASI has closed below the lower band by 8.7%. If price is in a downtrend band; this downward trend in price might continue. However a short term pullback inside the band is likely. Bollinger Bands are 39.5% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Headline News

The Daily Biotech Pulse: FDA Nod For Sanofi, BioCryst's Edema Drug In Japan, Myriad's Q1 Disappointment
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Nov. 4) Agile Therapeutics Inc (NASDAQ: AGRX )(follow-on rally following positive Adcom verdict for Twirla) Amgen, Inc. (NASDAQ: AMGN ) Beigene Ltd (NASDAQ: BGNE ) Bioanalytical Systems, Inc. (NASDAQ: BASI ) Bio-Rad Laboratories, Inc. (NYSE: BIO ) Cabaletta Bio Inc (NASDAQ: CABA ) Deciphera Pharmaceuticals Inc (NASDAQ: DCPH ) Frequency Therapeutics Inc (NASDAQ: FREQ ) Horizon Therapeutics PLC (NASDAQ: HZNP ) Karyopharm Therapeutics Inc (NASDAQ: KPTI )(reacted to its third-quarter results) Oyster Point Pharma Inc (NASDAQ: OYST ) (IPOed Oct. 31) Phathom Pharmaceuticals Inc (NASDAQ: PHAT ) Recro Pharma Inc (NASDAQ: REPH ) ZEALAND PHARMA/S ADR (NASDAQ: ZEAL ) Down In The Dumps (Biotech stocks hitting 52-week lows on Nov. 4) Cleveland BioLabs, Inc. (NASDAQ: CBLI ) Helius Medical Technologies Inc (NASDAQ: HSDT ) Mersana Therapeutics Inc (NASDAQ: MRSN ) Midatech Pharma PLC-ADR (NASDAQ: MTP ) Rockwell Medical Inc (NASDAQ: RMTI ) Tetraphase Pharmaceuticals Inc (NASDAQ: TTPH ) Stocks In Focus Seattle Genetics Claims Rights To Disputed Antibody-Drug Conjugate Intellectual Property Following the filing of a declaratory judgment action by DAIICHI SANKYO/S ADR (OTC: DSNKY ), Seattle Genetics, Inc. (NASDAQ: SGEN ) said the antibody-drug conjugate tech used in Daiichi Sankyo's metastatic cancer drug candidate DS-820 , among others, rightfully belongs to it. "The linker and other ADC technology used in these drug candidates are improvements to Seattle Genetics' pioneering ADC technology, the ownership of which are automatically assigned to Seattle Genetics under the terms of the agreement," the company said.

The Daily Biotech Pulse: Mirati Tastes Success With KRAS Inhibitor, Roche-Spark Deal Delayed Further, Morphosys Halts Study
The following is a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs Oct. 28.) AstraZeneca plc (NYSE: AZN ) ( reported positive clinical readout for triple combo lung cancer drug) Bioanalytical Systems, Inc. (NASDAQ: BASI ) Cabaletta Bio Inc (NASDAQ: CABA ) (went public Oct. 25) ESSA Pharma Inc (NASDAQ: EPIX ) IGM Biosciences Inc (NASDAQ: IGMS ) Novo Nordisk A/S (NYSE: NVO ) Reata Pharmaceuticals Inc (NASDAQ: RETA ) Seattle Genetics, Inc. (NASDAQ: SGEN ) Y-mAbs Therapeutics, Inc (NASDAQ: YMAB ) (reacted to a positive clinical readout) Down In The Dumps (Biotech stocks that hit 52-week lows Oct. 28.) Agile Therapeutics Inc (NASDAQ: AGRX ) (reported negative comments from FDA staff in the briefing document posted ahead of Twirla Adcom meeting) Bellerophon Therapeutics Inc (NASDAQ: BLPH ) CytomX Therapeutics Inc (NASDAQ: CTMX ) Diffusion Pharmaceuticals Inc (NASDAQ: DFFN ) Gritstone Oncology Inc (NASDAQ: GRTS ) Endologix, Inc. (NASDAQ: ELGX (FDA issued a safety communication to physicians and patients regarding Endologix AFX endovascular grafts) Hoth Therapeutics Inc (NASDAQ: HOTH ) KemPharm Inc (NASDAQ: KMPH ) Miragen Therapeutics Inc (NASDAQ: MGEN ) Mirum Pharmaceuticals Inc (NASDAQ: MIRM ) MOTIF BIO PLC/S ADR (NASDAQ: MTFB ) Myovant Sciences Ltd (NYSE: MYOV ) Orgenesis Inc (NASDAQ: ORGS ) Tonix Pharmaceuticals Holding Corp (NASDAQ: TNXP ) Stocks In Focus Mirati's KRAS Inhibitor Shows Tumor Shrinkage Mirati Therapeutics Inc (NASDAQ: MRTX ) announced the first Phase 1/2 trial results for MRTX849, an investigational KRAS G12C inhibitor, in patients with solid tumors expressing KRAS G12C mutations.

Financial Analysis

Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing.
Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs.
Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry.
Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not.
Click here to get more fundamental analysis.
Tweet this page Share on Facebook
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ Capital Market
Sector:  Healthcare
Industry:  Diagnostics Research
Shares Out. (M) 10.82
Shares Float (M) 6.97
% Held by Insiders 33.95
% Held by Institutions 8.04
Shares Short (K) 44
Shares Short P. Month (K)

Stock Financials

EPS -0.080
Book Value (p.s.) 1.020
PEG Ratio
Profit Margin -1.81
Operating Margin 0.66
Return on Assets (ttm) 0.5
Return on Equity (ttm) -7.3
Qtrly Rev. Growth 64.5
Gross Profit (p.s.) 1.194
Sales Per Share
EBITDA (p.s.) 0.277
Qtrly Earnings Growth
Operating Cash Flow (M) 1.78
Levered Free Cash Flow (M) -4.80

Stock Valuations

P/E -57.63
P/E Growth Ratio -0.07
P/BV 4.52
P/S 1.09
P/CF 28.02

Dividends & Splits

Dividend Yield
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Forward Dividend
Last Split Date
Last Split Ratio -1e+010
7 Binary Options
Your Ad Here
Stock Chart
Stoxline Lite
Stoxline Pro
Option Calculator
(c) 2006-2019 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.